Ulaanbaatar, Mongolia. March 20, 2019. On the morning of Tuesday, March 19, the training program of the Mongolian medical specialists of The First Hospital of Ulaanbaatar for the use and application of the Cuban biotechnological product Heberprot-P began. As a result of the MoU signed on February 23, between this health institution, the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba and the Mongolian pharmaceutical company Mongolian Import and Export Concern, the training program will feature master classes, conferences and specialized consultations that will be given by Dr. Yanisbel Ortiz Peña, 1st Degree Specialist in Angiology and Vascular Surgery of the CIGB.
The Director General of The First Hospital of Ulaanbaatar, Dr. Chuluunbaatar Donkhim said during the training opening session that the registration of Heberprot-P in Mongolia, and its application to patients affected with diabetic foot ulcers in public hospitals in the country will give the possibility of reducing amputations and other effects on the health of these patients. For the training a group of doctors of different medical specialties necessary for the control and treatment of diabetes have been selected, they will receive the training and protocol to follow for the use of this medicine.
The registration of this novel Cuban biotechnological product and the transfer of knowledge for its use and application, has been one of the main achievements of the Cuban Center for Genetic Engineering and Biotechnology in scientific and commercial matters in Mongolia, whose exceptional results open the possibility of continuing marketing other products that will improve the health indexes of this Asian center nation. (EmbaCuba Mongolia)